Figure 5.

SLAMF7 expression across the TME and tumor inflating myeloid cell phenotypes following Ad-SF7-Fc treatment

(A) SLAMF7 expression across immune cell subsets in B16 tumors after Ad-null treatment. (B) DC subsets in tumors treated with either Ad-null or Ad-SF7-Fc clustered with FlowSOM and displayed with UMAP. (C) Marker expression from clusters in (B). (D) CD38 and SLAMF7 expression displayed on UMAP plot of DCs from (B). (E) Frequency of DC subsets between mice whose B16 tumors respond to I.T. adenovirus treatment or not. (F) Cytokine and chemokine expression from Ad-null and Ad-SF7-Fc treated B16 tumors. (G) TAM subsets in tumors treated with either Ad-null or Ad-SF7-Fc clustered with FlowSOM and displayed with UMAP. (H) Marker expression from clusters in (G). (I) Co-expression of SLAMF7 and PD-L1 on all TAMs (colored by subset). (J) Spearman's correlation coefficient of SLAMF7 and PD-L1 on all immune cell subsets from B16 tumors treated with adenovirus. A generalized linear mixed model was used to compare groups in (E). An unpaired, two-tailed t test used to compare groups in (F). All data representative of two independent experiments showing similar results. AF = autofluorescence.